Lymphocyte P-glycoprotein variability in healthy individuals

Medicina

Volumn 69, Issue 6, 2009, Pages 619-624

  Cortada, Catalina M ^a   Escobar, Anahi ^a   Bramuglia, Guillermo F ^a   Niselman, A Viviana ^a   Carballo, Marta Ana ^a   Rubio, Modesto C ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

ABCB1; Drug transporters; P glycoprotein; Rh123 efflux assay

Indexed keywords

GLYCOPROTEIN P; RHODAMINE 123; VALSPODAR; VERAPAMIL;

ADULT; AGED; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KOLMOGOROV SMIRNOV TEST; LYMPHOCYTE; MALE; NORMAL HUMAN; PROTEIN FUNCTION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ARGENTINA; DRUG RESISTANCE, MULTIPLE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLUORESCENT DYES; HUMANS; LYMPHOCYTES; MALE; MIDDLE AGED; P-GLYCOPROTEIN; RHODAMINE 123; SEX DISTRIBUTION; SEX FACTORS; YOUNG ADULT;

EID: 75149128567     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Zhang L, Strong JM, Qiu W, Lesko LJ, Huang S-M. Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm 2006; 3: 62-9.
2. Schinkel AH, Jonker JW. Mammalian drug efflux. transporters of the ATP binding cassette (ABC) family: an overview Adv. Drug Deliv Rev 2003; 55: 3-29.
3. Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007; 446: 749-57.
4. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-62.
5. Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Cancer Biology 1997; 8: 161-70.
6. Schinkel AH. Absence of the Mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96: 1698-705.
7. Mayer U, Wagenaar E, Beijnen J et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol 1996; 119: 1038-44.
8. Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992; 80: 2735-39.
9. Arbelbide J, García Rivello H, Tacchi M, et al. Importancia pronóstica de la expresión de MDR-1 en la leucemia mieloblástica aguda. Medicina (Buenos Aires) 2003; 63: 277-82.
10. Borst P, Schinkel A. Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet 1997; 13: 217-22.
11. Chang G. Multidrug resistance ABC transporters. FEBS Lett 2003; 555: 102-5.
12. Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004; 25: 423-9
13. Hitzl M, Drescher S, van der Kuip H et al. The C3435T mutation in the human MDR1gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 2001; 11: 293-8.
14. Bøyum A. Separation of white blood cells. Nature 1964; 204: 793-4.
15. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem-cells. Cell 1991; 66: 85-94.
16. Marie J-P, Huet S, Faussat A-M et al. Multicentric evaluation of the MDR phenotype in leukemia. Leukemia 1997; 11: 1086-94.
17. Massey F. The Kolmogorov-Smirnov test of goodness of fit. J Am Stat Assoc 1951; 46: 70.
18. nd Edition, New York: John Wiley Sons Inc., 1981, p 25-7.
19. Hollander M, Wolfe D. The Mann- Whitney nonparametric test for two samples. Nonparametric Statistical Methods New York-London-Sydney-Toronto: Ed J Wiley & Sons. 1999: 67-82.
20. Zhang Y, Bachmeier C, Miller DW. In vitro and in vivo models for assessing drug efflux transporter activity. Adv Drug Deliv Rev 2003; 55: 31-51.
21. Klimecky WT, Futscher W, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994; 83: 2451-8.
22. Gandhi M, Aweeka F, Greenblatt RM, Biaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 2004; 44: 499-523.
23. von Richter O, Burk O, Fromm M, Thon K, Eichelbaum M, Kivistö K. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004; 75: 172-83.
24. Fromm RB. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv Drug Deliv Rev 2002; 54: 1295-310.
25. Kim R. Drug transporters in HIV therapy. Top HIV Med 2003; 11: 136-9.
26. Bramuglia F, Cortada C, Curras V, Hocht C, Buontempo F, Mato G et al. Relationship between P-glycoprotein activity measured in peripheral blood mononuclear cells and indinavir bioavailability in healthy volunteers. J Pharmacol Sci 2009; 98: 327-36.
27. Larioa AP, Garcia CB, Elizondo ME, Lobo C. Expression of proteins associated with multidrug resistance and resistance to chemotherapy in lung cancer. Archivos De Bronconeumologia 2007; 43: 481-4.
28. Oselin K, Gerloff T, Mrozikiewicz PM, Pähkla R, Roots I. MRD1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fund Clin Pharmacol 2003; 17: 463-9.
29. Xie HG, Kim RB, Wood AJJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50.